Acurx Pharmaceuticals (ACXP) Research & Development (2020 - 2026)
Acurx Pharmaceuticals' (ACXP) quarterly Research & Development came in at $341468.0 in Q1 2026, down 42.97% YoY from $598798.0 in Q1 2025, and up 21.17% on a QoQ basis from $281807.0 in Q4 2025.
Acurx Pharmaceuticals (ACXP) Research & Development (2020 - 2026) Analysis & Trends
Acurx Pharmaceuticals (ACXP) has 7 years of Research & Development data on file, last reported at $341468.0 in Q1 2026.
- Quarterly Research & Development fell 42.97% year-over-year to $341468.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.6 million (down 64.54% YoY) and the FY2025 annual result came in at $1.8 million, down 66.05% from the prior year.
- Research & Development climbed to $341468.0 in Q1 2026, from $281807.0 in the prior quarter.
- In the past five years, Research & Development ranged from a high of $1.9 million in Q4 2023 to a low of $281807.0 in Q4 2025.
- A 5-year average of $1.1 million and a median of $1.0 million in 2023 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2022 — Research & Development surged 858.93% — and 2025, when it slumped 71.29%.
- Tracing ACXP's Research & Development over 5 years: stood at $1.4 million in 2022, then soared by 35.6% to $1.9 million in 2023, then sank by 57.53% to $825059.0 in 2024, then tumbled by 65.84% to $281807.0 in 2025, then gained by 21.17% to $341468.0 in 2026.
- The last three Research & Development figures came in at $341468.0 (Q1 2026), $281807.0 (Q4 2025), and $429691.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Acurx Pharmaceuticals | 6.18 Mn | 6.18 Mn | - | 1.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.07 Mn |
| Mar 31, 2026 | 341,468.00 |
| Dec 31, 2025 | 281,807.00 |
| Sep 30, 2025 | 429,691.00 |
| Jun 30, 2025 | 524,210.00 |
| Mar 31, 2025 | 598,798.00 |
| Dec 31, 2024 | 825,059.00 |
| Sep 30, 2024 | 1.20 Mn |
| Jun 30, 2024 | 1.83 Mn |
| Mar 31, 2024 | 1.56 Mn |
| Dec 31, 2023 | 1.94 Mn |
| Sep 30, 2023 | 1.35 Mn |
| Jun 30, 2023 | 1.74 Mn |
| Mar 31, 2023 | 1.02 Mn |
| Dec 31, 2022 | 1.43 Mn |
| Sep 30, 2022 | 1.59 Mn |
| Jun 30, 2022 | 911,692.00 |
| Mar 31, 2022 | 818,888.00 |
| Dec 31, 2021 | 716,223.00 |
| Sep 30, 2021 | 1.13 Mn |